<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27191857</article-id><article-id pub-id-type="pmc">4871457</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0155604</article-id><article-id pub-id-type="publisher-id">PONE-D-15-45356</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmaceutics</subject><subj-group><subject>Drug Therapy</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Model Organisms</subject><subj-group><subject>Animal Models</subject><subj-group><subject>Rats</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Animals</subject><subj-group><subject>Vertebrates</subject><subj-group><subject>Amniotes</subject><subj-group><subject>Mammals</subject><subj-group><subject>Rodents</subject><subj-group><subject>Rats</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Cognitive Science</subject><subj-group><subject>Cognition</subject><subj-group><subject>Decision Making</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Neurochemistry</subject><subj-group><subject>Neurochemicals</subject><subj-group><subject>Opiates</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Neurochemistry</subject><subj-group><subject>Neurochemicals</subject><subj-group><subject>Opiates</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Model Organisms</subject><subj-group><subject>Animal Models</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Mathematical and Statistical Techniques</subject><subj-group><subject>Statistical Methods</subject><subj-group><subject>Analysis of Variance</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics (Mathematics)</subject><subj-group><subject>Statistical Methods</subject><subj-group><subject>Analysis of Variance</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Addiction</subject><subj-group><subject>Gambling Addiction</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social Sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Addiction</subject><subj-group><subject>Gambling Addiction</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Mental Health and Psychiatry</subject><subj-group><subject>Gambling Addiction</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Cognitive Science</subject><subj-group><subject>Cognitive Neuroscience</subject><subj-group><subject>Cognitive Neurology</subject><subj-group><subject>Cognitive Impairment</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Cognitive Neuroscience</subject><subj-group><subject>Cognitive Neurology</subject><subj-group><subject>Cognitive Impairment</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Cognitive Neurology</subject><subj-group><subject>Cognitive Impairment</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Evaluating the Impact of Naltrexone on the Rat Gambling Task to Test Its Predictive Validity for Gambling Disorder</article-title><alt-title alt-title-type="running-head">Naltrexone and Gambling</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Di Ciano</surname><given-names>Patricia</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Le Foll</surname><given-names>Bernard</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref><xref ref-type="aff" rid="aff004"><sup>4</sup></xref><xref ref-type="aff" rid="aff005"><sup>5</sup></xref><xref ref-type="aff" rid="aff006"><sup>6</sup></xref><xref ref-type="aff" rid="aff007"><sup>7</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Translational Addiction Research Laboratory, CAMH, Toronto, Canada</addr-line></aff><aff id="aff002"><label>2</label><addr-line>Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada</addr-line></aff><aff id="aff003"><label>3</label><addr-line>Department of Psychiatry, University of Toronto, Toronto, Canada</addr-line></aff><aff id="aff004"><label>4</label><addr-line>Campbell Family Mental Health Research Institute, CAMH, Toronto, Canada</addr-line></aff><aff id="aff005"><label>5</label><addr-line>Ambulatory Care and Structured Treatment Program, CAMH, Toronto, Canada</addr-line></aff><aff id="aff006"><label>6</label><addr-line>Institute of Medical Sciences, University of Toronto, Toronto, Canada</addr-line></aff><aff id="aff007"><label>7</label><addr-line>Department of Family and Community Medicine, University of Toronto, Toronto, Canada</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Pattij</surname><given-names>Tommy</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>VU University Medical Center, NETHERLANDS</addr-line></aff><author-notes><fn fn-type="conflict" id="coi001"><p><bold>Competing Interests: </bold>Bernard Le Foll is a PLOS ONE Editorial Board member. This does not alter the authors' adherence to PLOS ONE Editorial policies and criteria.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: PDC BLF. Performed the experiments: PDC. Analyzed the data: PDC. Wrote the paper: PDC BLF.</p></fn><corresp id="cor001">* E-mail: <email>Bernard.lefoll@camh.ca</email></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>5</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>11</volume><issue>5</issue><elocation-id>e0155604</elocation-id><history><date date-type="received"><day>15</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>2</day><month>5</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 Di Ciano, Le Foll</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Di Ciano, Le Foll</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0155604.pdf"/><abstract><p>Gambling Disorder has serious consequences and no medications are currently approved for the treatment of this disorder. One factor that may make medication development difficult is the lack of animal models of gambling that would allow for the pre-clinical screening of efficacy. Despite this, there is evidence from clinical trials that opiate antagonists, in particular naltrexone, may be useful in treating gambling disorder. To-date, the effects of naltrexone on pre-clinical models of gambling have not been evaluated. The purpose of the present study was to evaluate the effects of naltrexone in an animal model of gambling, the rat gambling task (rGT), to determine whether this model has some predictive validity. The rGT is a model in which rats are given a choice of making either a response that produces a large reward or a small reward. The larger the reward, the greater the punishment, and thus this task requires that the animal inhibit the &#x02018;tempting&#x02019; choice, as the smaller reward option produces overall the most number of rewards per session. People with gambling disorder chose the tempting option more, thus the rGT may provide a model of problem gambling. It was found that naltrexone improved performance on this task in a subset of animals that chose the &#x02018;tempting&#x02019;, disadvantageous choice, more at baseline. Thus, the results of this study suggest that the rGT should be further investigated as a pre-clinical model of gambling disorder and that further investigation into whether opioid antagonists are effective in treating Gambling Disorder may be warranted.</p></abstract><funding-group><award-group id="award001"><funding-source><institution>Centre for Addiction and Mental Health</institution></funding-source><principal-award-recipient><name><surname>Le Foll</surname><given-names>Bernard</given-names></name></principal-award-recipient></award-group><funding-statement>This study was supported by the Centre for Addiction and Mental Health.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="2"/><page-count count="13"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Gambling Disorder is a serious health concern for those afflicted, and this is underscored by the reclassification of gambling as an addictive disorder in the recently released DSM-5. To-date, there are no approved pharmacological treatments for pathological gambling. Part of the reason why this is the case is that gambling remains difficult to evaluate in the pre-clinical stages of testing, when its early efficacy is evaluated in animal models. A number of animal models of gambling have been developed [<xref rid="pone.0155604.ref001" ref-type="bibr">1</xref>], but their predictive validity remains to be determined, thus making the testing of potential new treatments difficult.</p><p>The rat gambling task (rGT) [<xref rid="pone.0155604.ref002" ref-type="bibr">2</xref>] is a relatively novel model of rodent gambling that is based on the Iowa gambling task in humans [<xref rid="pone.0155604.ref003" ref-type="bibr">3</xref>]. In this task, humans are given a choice of decks of cards. Each deck of cards is associated with different probabilities of reward and punishment such that the deck with higher reward also produces higher punishment. Although the decks with the higher rewards are the &#x02018;tempting&#x02019; options, these choices must be inhibited, as the lower rewarded decks produce the greatest number of rewards in a given time period. In rats, this is modeled in the rGT by training the rats that 4 different response holes are associated with different amounts of reward and punishment.</p><p>The purpose of the present study is to evaluate the predictive validity of the rGT by determining whether treatments that have shown some efficacy in human clinical trials also show an effect on the rGT. We decided to investigate the opioid antagonist, naltrexone, as it has been consistently shown in humans that treatment with naltrexone diminished gambling urges and behaviour in both clinical trials [<xref rid="pone.0155604.ref004" ref-type="bibr">4</xref>&#x02013;<xref rid="pone.0155604.ref009" ref-type="bibr">9</xref>] and in case studies [<xref rid="pone.0155604.ref010" ref-type="bibr">10</xref>, <xref rid="pone.0155604.ref011" ref-type="bibr">11</xref>]. These findings were supported by the further findings that nalmefene, an opiate antagonist, also reduced subjective indices of gambling in humans [<xref rid="pone.0155604.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0155604.ref013" ref-type="bibr">13</xref>]. Thus, the opiate antagonists are a useful class of drug to investigate and naltrexone was used in the present study.</p><p>In humans, pathological gamblers peforming the Iowa Gambling Task make suboptimal choices by choosing the decks with higher rewards [<xref rid="pone.0155604.ref014" ref-type="bibr">14</xref>], despite the overall fewer rewards obtained over a session with this option. Thus, by analogy, we have subdivided the present group of rats into two subsets, consisting of whether they preferred to make Advantageous or Disadvantageous choices at baseline [<xref rid="pone.0155604.ref015" ref-type="bibr">15</xref>]. It was hypothesized that naltrexone will increase Advantageous choice in the suboptimal group making more Disadvantageous choices at baseline, and have no effect on the optimal group.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Methods</title><sec id="sec003"><title>Subjects</title><p>Subjects were 24 male Long Evans rats (Charles River, St. Constant, QC) weighing 250&#x02013;300g at the start of the study. The sample size was determined based on previous studies. All animals were single-housed in a climate-controlled environment on a 12-h reverse light/dark cycle (lights off 8.00am&#x02013;8.00pm) so that behavioral testing occurred during the active phase of the animals&#x02019; circadian rhythm. During behavioral testing, rats were maintained on 18&#x02013;20g of rat chow per day, given after their experimental session. This results in sufficient motivation for food to ensure an adequate number of trials/sessions but also allows for continued growth during the study. Water was available <italic>ad libitum</italic> in their home cages. This study was carried out in strict accordance with the recommendations by the Canadian Council on Animal Care. The protocol was approved by the Centre for Addiction and Mental Health Animal Care Committee. All efforts were made to minimize suffering.</p></sec><sec id="sec004"><title>Behavioral Equipment</title><p>Behavioral testing occurred in five-hole operant chambers (Med Associates, Roanoke, VA; the same chambers used for the five-choice serial reaction time task). The boxes were controlled by software written in Med PC running on an IBM compatible computer. The defining feature of such boxes is that an array of five stimulus&#x02013;response holes is located on one wall of the chamber, although only the four outer holes are used during the task. Each response hole can be illuminated by a stimulus light located therein, and nose-poke responses into a hole are detected by an infrared sensor. A food tray, also equipped with an infrared sensor and a tray light, is located in the middle of the opposite wall, into which pellets can be delivered via an external pellet dispenser. The entire chamber can also be illuminated using a house-light.</p></sec><sec id="sec005"><title>The Rat Gambling Task</title><p>In the rGT, animals learn about which response option has which size of reward and probability/duration of a time-out punishment (BioServ 45 mg Rodent Purified Diet, product #F0021). For details of the training, see [<xref rid="pone.0155604.ref002" ref-type="bibr">2</xref>]. Briefly, rats were first trained on the 5 choice serial reaction time task (5-CSRT) for 13 days, followed by 7 days of forced choice training. Forced choice training was essentially the same as the 5-CSRT task, but each hole was associated with a different probability of rewards and punishment (see <xref ref-type="table" rid="pone.0155604.t001">Table 1</xref>). The purpose of forced choice training was for the rat to learn which hole produced which size and probability of reward and punishment. After forced choice, rats began training on the rGT.</p><table-wrap id="pone.0155604.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0155604.t001</object-id><label>Table 1</label><caption><title>Reward and punishment received for the various response options in the rGT.</title></caption><alternatives><graphic id="pone.0155604.t001g" xlink:href="pone.0155604.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Group A</bold></td><td align="center" rowspan="1" colspan="1">hole 1</td><td align="center" rowspan="1" colspan="1">hole 4</td><td align="center" rowspan="1" colspan="1">hole 5</td><td align="center" rowspan="1" colspan="1">hole 2</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Group B</bold></td><td align="center" rowspan="1" colspan="1">hole 2</td><td align="center" rowspan="1" colspan="1">hole 5</td><td align="center" rowspan="1" colspan="1">hole 4</td><td align="center" rowspan="1" colspan="1">hole 1</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Choice</bold></td><td align="center" rowspan="1" colspan="1">P1</td><td align="center" rowspan="1" colspan="1">P2</td><td align="center" rowspan="1" colspan="1">P3</td><td align="center" rowspan="1" colspan="1">P4</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Reward (# pellets)</bold></td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Punishment Duration</bold></td><td align="center" rowspan="1" colspan="1">5s</td><td align="center" rowspan="1" colspan="1">10s</td><td align="center" rowspan="1" colspan="1">30s</td><td align="center" rowspan="1" colspan="1">40s</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Punishment Probability</bold></td><td align="center" rowspan="1" colspan="1">0.1</td><td align="center" rowspan="1" colspan="1">0.2</td><td align="center" rowspan="1" colspan="1">0.5</td><td align="center" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Rewards Possible</bold></td><td align="center" rowspan="1" colspan="1">295</td><td align="center" rowspan="1" colspan="1">411</td><td align="center" rowspan="1" colspan="1">135</td><td align="center" rowspan="1" colspan="1">99</td></tr></tbody></table></alternatives></table-wrap><p>In the rGT, animals initiate each trial by making a nosepoke response at the food tray (with a traylight). This triggers the start of a 5 s inter-trial interval (ITI) before the stimulus lights are turned on in all of the four active holes. A response at one of the illuminated holes results in the offset of all the stimulus lights and either delivery of the pre-set amount of reward for that hole option, or the start of the time-out &#x0201c;punishment&#x0201d; period. Sessions lasted for 30 minutes. The following is a summary of possible outcomes:</p><list list-type="order"><list-item><p>Reward: If the animal is rewarded on any trial, food delivery is signalled by onset of the traylight which remains illuminated until the animal collects the reward. Responding at the food tray also initiates the start of the next trial. The size of reward and punishment probability/duration is given in <xref ref-type="table" rid="pone.0155604.t001">Table 1</xref>.</p></list-item><list-item><p>Punishment: If the animal is punished, the traylight remains off until the end of the time-out period, whereupon this light is turned on to signal that the animal can initiate the next trial. During these time-out periods, the stimulus light within the hole chosen on that trial flashes at a frequency of 0.5 Hz. The size of reward and punishment probability/duration is given in <xref ref-type="table" rid="pone.0155604.t001">Table 1</xref>.</p></list-item><list-item><p>Omission: If the animal fails to make a response within 10 seconds after the four stimulus lights are turned on, the stimulus lights are turned off, the trial is scored as an omission and the traylight is illuminated to signal the beginning of the next trial. Animals are not punished for omitting trials.</p></list-item><list-item><p>Premature responses: Premature responses made at the array during the ITI are punished by a 5 s time-out period during which no further trials can be initiated. The duration of the time-out is signalled by illumination of the houselight, and terminated by onset of the traylight so that animals can begin another trial.</p></list-item></list><p>Training continued until a stable pattern of choice between the four options was observed (approximately 30 sessions). Animals were randomly assigned to one of two groups (A or B), receiving a different configuration of response outcomes in the holes (<xref ref-type="table" rid="pone.0155604.t001">Table 1</xref>).</p></sec><sec id="sec006"><title>Drug</title><p>Naltrexone (Sigma-Aldrich, Oakville, ONT, Canada) was administered acutely at doses of 0, 1, 3, or 10 mg/kg, i.p. and given in counterbalanced order at a volume of 1ml/kg. Naltrexone was dissolved in sterile saline, aliquoted and frozen (no longer than one month) and administered i.p. 30 minutes prior to the test session on the day of testing. Doses of naltrexone were chosen based on previous studies [<xref rid="pone.0155604.ref016" ref-type="bibr">16</xref>]. Doses were administered in a Latin-square design. Prior to receiving any naltrexone injections, rats were given 0.3 ml of saline i.p. for at least 2 days to habituate them to the testing procedure. At least two days of stable responding on the rGT without any treatment separated each naltrexone treatment day. Rats were trained on the rGT for approximately 30 days prior to the start of drug testing.</p></sec><sec id="sec007"><title>Data Analyses</title><sec id="sec008"><title>Measures</title><p>The measures chosen are based on Zeeb et al. (2009) [<xref rid="pone.0155604.ref002" ref-type="bibr">2</xref>], which are predicated by studies of the 5 Choice Serial Reaction Time Task. For a discussion of the interpretation of these measures, see Robbins (2002) [<xref rid="pone.0155604.ref017" ref-type="bibr">17</xref>]. The measures collected are: 1) the percentage of trials on which an animal chose a particular option (number of choices of a particular option /number of trials (including omissions) *100). Choice data was arcsine transformed [<xref rid="pone.0155604.ref002" ref-type="bibr">2</xref>]; 2) The total number of trials initiated; 3) Omissions made expressed as a percentage of the total number of trials initiated; 4) Premature responses expressed as a percentage of the total number of trials initiated; 5) The latency to make a choice after initiation of a trial; 6) The latency to collect reward after making a response choice; 7) Perseverative responses on punished and rewarded trials calculated as the fraction of the total punishment duration or total number of trials rewarded</p></sec><sec id="sec009"><title>Choice and Optimal vs Suboptimal</title><p>In the rGT, rats must learn the optimal strategy to obtain the most number of reinforcements per session as possible. To achieve this, rats must inhibit the choice that produces large rewards because this also results in the greatest punishment; choices with smaller rewards produce more pellets per session. In the rGT, there are four choice options, P1, P2, P3 and P4 that produce 1, 2, 3 or 4 pellets, respectively. If the rats choose exclusively one option, the number of pellets possible would be greatest with P2 (411), then with P1 (295), then P3 (135), with P4 (99) producing the fewest number of pellets (see <xref ref-type="table" rid="pone.0155604.t001">Table 1</xref>) [<xref rid="pone.0155604.ref002" ref-type="bibr">2</xref>]. Thus, P1 and P2 are optimal strategies, while P3 and P4 are suboptimal &#x02018;tempting&#x02019; strategies. In the Iowa gambling task, it is known that pathological gamblers choose these &#x02018;tempting&#x02019; options [<xref rid="pone.0155604.ref014" ref-type="bibr">14</xref>, <xref rid="pone.0155604.ref018" ref-type="bibr">18</xref>]. Therefore, the percent choice of P1 was added to the percent choice of P2 to comprise the &#x02018;Advantageous&#x02019; option, while P3 and P4 percent choices were summed to produce the &#x02018;Disadvantageous&#x02019; option. Rats that made more advantageous choices (50% advantageous choice or greater) under vehicle were analyzed as the &#x02018;Optimal&#x02019; group, while those that made more disadvantageous than advantageous choices (50% disadvantageous choices or greater) under vehicle were the &#x02018;Suboptimal&#x02019; group.</p></sec><sec id="sec010"><title>Analysis of Choices P1 to P4</title><p>The effects of naltrexone on percent choice for each of P1, P2, P3 and P4 was analyzed with a Dose (4 levels) X Group (2 levels; Optimal, Suboptimal) X Choice (4 levels; P1, P2, P3, P4) mixed ANOVA with Group as the between-subjects factor. A significant interaction was followed by <italic>t</italic>-test with Bonferroni correction.</p></sec><sec id="sec011"><title>Analysis of Optimal vs Suboptimal Choices and Other Measures</title><p>For all measures, data was analyzed with two-way mixed ANOVAs on Dose (4 levels) X Group (2 levels). Significant effects were followed up with <italic>t</italic>-tests using the Bonferroni correction. All statistical analyses were conducted using SPSS for Windows with a criteria for significance of p&#x0003c;0.05.</p></sec><sec id="sec012"><title>Distribution of Responses as Either Optimal or Suboptimal</title><p>To determine the distribution of either optimal or suboptimal responding, the percentage of advantageous choices made was presented as a frequency distribution at either 0&#x02013;10, 11&#x02013;20, 21&#x02013;30, 31&#x02013;40, 41&#x02013;50, 51&#x02013;60, 71&#x02013;80 or 91&#x02013;100 percent of advantageous choices.</p></sec><sec id="sec013"><title>Stability of Responding</title><p>To demonstrate stability of responding across testing days, the percent of advantageous choices on the day prior to any drug treatments was compared to the percent of advantageous choices made on the day prior to the last drug treatment. Data was analyzed with a Group (2 levels; Optimal vs Suboptimal) X Day (2 levels; day before first drug treatment vs day before last drug treatment) mixed ANOVA with Group as the between-subjects factor.</p></sec></sec></sec><sec sec-type="results" id="sec014"><title>Results</title><p>The final group sizes were optimal = 15 and suboptimal = 9. All rats consumed all food pellets after all sessions.</p><sec id="sec015"><title>Analysis of Choice</title><p>A Group X Dose X Choice ANOVA revealed an overall interaction that approached significance (F(9, 198) = 1.823, p = 0.066; <xref ref-type="fig" rid="pone.0155604.g001">Fig 1</xref>). Dose X Group ANOVAs revealed a significant interaction for P1 only (F(3, 66) = 3.256, p<sub>GG</sub> = 0.047). Follow-up <italic>t</italic>-tests revealed that the difference between vehicle and the 3mg/kg (t(8) = -3.298, p = .011) and vehicle and the 10 mg/kg dose (t(8) = -2.328, p = 0.048) were significant (p&#x0003c;0.05) for the suboptimal group, indicating that naltrexone increased responding for P1 in the Suboptimal rats. Only the comparison of 3 mg/kg to vehicle was significant after correction for multiple comparison (p&#x0003c;0.0167). See <xref ref-type="fig" rid="pone.0155604.g001">Fig 1</xref>.</p><fig id="pone.0155604.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0155604.g001</object-id><label>Fig 1</label><caption><p><bold>Mean + SEM percent choice of the P1 (top left panel), P2 (top right panel), P3 (bottom left panel) and P4 (bottom right panel) options.</bold> Data are presented for the Optimal (n = 15; open bars) and Suboptimal (dark bars, n-9) groups. Dose X Group ANOVAs revealed a significant interaction for P1 (F(3, 66) = 3.256, p<sub>GG</sub> = 0.047). *significant <italic>t</italic>-tests after correction for multiple comparisons.</p></caption><graphic xlink:href="pone.0155604.g001"/></fig></sec><sec id="sec016"><title>Advantageous, Disadvantageous Responding and Other Measures</title><p>Analysis of behavioral measures with Group X Dose ANOVAs revealed a significant interaction for Advantageous responding (F(3, 66) = 2.988, p = 0.037; <xref ref-type="fig" rid="pone.0155604.g002">Fig 2</xref>). Comparison of each dose to vehicle with <italic>t</italic>-tests revealed no significant effects, but the comparison of 10 mg/kg to vehicle approached significance for the disadvantageous group, when not corrected for multiple comparisons (p = 0.056). Analysis of other measures with Dose X Group ANOVAs did not reveal any significant interactions, but a main effect of Group was found for number of trials (F(1, 22) = 6.110, p = 0.022) (<xref ref-type="table" rid="pone.0155604.t002">Table 2</xref>), indicating that the Suboptimal group initiated fewer trials than the Optimal group.</p><fig id="pone.0155604.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0155604.g002</object-id><label>Fig 2</label><caption><title>Mean + SEM percent choice for the advantageous choice at different doses of naltrexone for the Optimal (open bars, n = 15) and Suboptimal (dark bars, n = 9) groups.</title><p>Group X Dose ANOVAs revealed a significant interaction for Advantageous responding (F(3, 66) = 2.988, p = 0.037).</p></caption><graphic xlink:href="pone.0155604.g002"/></fig><table-wrap id="pone.0155604.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0155604.t002</object-id><label>Table 2</label><caption><title>Effect of naltrexone on other measures of the rGT for the Optimal (n = 15) and Suboptimal (n = 9) groups.</title><p>Dose X Group ANOVAs revealed no significant interactions or main effects. Data presented are mean &#x000b1; SEM. *Indicated a main effect of Group (p&#x0003c;0.05).</p></caption><alternatives><graphic id="pone.0155604.t002g" xlink:href="pone.0155604.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">VARIABLE</th><th align="center" rowspan="1" colspan="1">GROUP</th><th align="center" colspan="4" rowspan="1">DOSES (mg/kg)</th></tr><tr><th align="left" colspan="2" rowspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Vehicle</th><th align="center" rowspan="1" colspan="1">1</th><th align="center" rowspan="1" colspan="1">3</th><th align="center" rowspan="1" colspan="1">10</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Trials</td><td align="left" rowspan="1" colspan="1">Optimal*</td><td align="left" rowspan="1" colspan="1">89.55 &#x000b1; 6.11</td><td align="left" rowspan="1" colspan="1">93.96 &#x000b1; 8.62</td><td align="left" rowspan="1" colspan="1">97.88 &#x000b1; 7.85</td><td align="left" rowspan="1" colspan="1">90.1 &#x000b1; 7.43</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Suboptimal</td><td align="left" rowspan="1" colspan="1">64.89 &#x000b1; 3.07</td><td align="left" rowspan="1" colspan="1">66.34 &#x000b1; 4.24</td><td align="left" rowspan="1" colspan="1">72.13 &#x000b1; 5.80</td><td align="left" rowspan="1" colspan="1">71.9 &#x000b1; 8.99</td></tr><tr><td align="left" rowspan="1" colspan="1">Omissions</td><td align="left" rowspan="1" colspan="1">Optimal</td><td align="left" rowspan="1" colspan="1">0.97 &#x000b1; 0.35</td><td align="left" rowspan="1" colspan="1">0.81 &#x000b1; 0.39</td><td align="left" rowspan="1" colspan="1">1.89 &#x000b1; 1.70</td><td align="left" rowspan="1" colspan="1">1.02 &#x000b1; 0.60</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Suboptimal</td><td align="left" rowspan="1" colspan="1">2.16 &#x000b1; 1.14</td><td align="left" rowspan="1" colspan="1">2.12 &#x000b1; 1.47</td><td align="left" rowspan="1" colspan="1">2.98 &#x000b1; 1.62</td><td align="left" rowspan="1" colspan="1">2.22 &#x000b1; 1.28</td></tr><tr><td align="left" rowspan="1" colspan="1">Premature Responding</td><td align="left" rowspan="1" colspan="1">Optimal</td><td align="left" rowspan="1" colspan="1">12.92 &#x000b1; 1.91</td><td align="left" rowspan="1" colspan="1">10.52 &#x000b1; 1.52</td><td align="left" rowspan="1" colspan="1">8.46 &#x000b1; 1.58</td><td align="left" rowspan="1" colspan="1">10.28 &#x000b1; 1.68</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Suboptimal</td><td align="left" rowspan="1" colspan="1">13.17 &#x000b1; 3.42</td><td align="left" rowspan="1" colspan="1">15.87 &#x000b1; 4.08</td><td align="left" rowspan="1" colspan="1">12.20 &#x000b1; 3.17</td><td align="left" rowspan="1" colspan="1">19.01 &#x000b1; 3.97</td></tr><tr><td align="left" rowspan="1" colspan="1">Reward Perseverative</td><td align="left" rowspan="1" colspan="1">Optimal</td><td align="left" rowspan="1" colspan="1">.020 &#x000b1; .01</td><td align="left" rowspan="1" colspan="1">.021 &#x000b1; .01</td><td align="left" rowspan="1" colspan="1">.012 &#x000b1; .01</td><td align="left" rowspan="1" colspan="1">.011 &#x000b1; .003</td></tr><tr><td align="left" rowspan="2" colspan="1">&#x000a0;</td><td align="left" rowspan="2" colspan="1">Suboptimal</td><td align="left" rowspan="2" colspan="1">.014 &#x000b1; .01</td><td align="left" rowspan="2" colspan="1">.032 &#x000b1; .02</td><td align="left" rowspan="2" colspan="1">.014 &#x000b1; .01</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">.010 &#x000b1; .004</td></tr><tr><td align="left" rowspan="1" colspan="1">Punishment Perseverative</td><td align="left" rowspan="1" colspan="1">Optimal</td><td align="left" rowspan="1" colspan="1">.051 &#x000b1; .01</td><td align="left" rowspan="1" colspan="1">.051 &#x000b1; .01</td><td align="left" rowspan="1" colspan="1">.048 &#x000b1; .01</td><td align="left" rowspan="1" colspan="1">.058 &#x000b1; .01</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Suboptimal</td><td align="left" rowspan="1" colspan="1">.032 &#x000b1; .01</td><td align="left" rowspan="1" colspan="1">.044 &#x000b1; .01</td><td align="left" rowspan="1" colspan="1">.039 &#x000b1; .01</td><td align="left" rowspan="1" colspan="1">.042 &#x000b1; .01</td></tr><tr><td align="left" rowspan="1" colspan="1">Choice Latency</td><td align="left" rowspan="1" colspan="1">Optimal</td><td align="left" rowspan="1" colspan="1">1.38 &#x000b1; .35</td><td align="left" rowspan="1" colspan="1">1.39 &#x000b1; .19</td><td align="left" rowspan="1" colspan="1">1.27 &#x000b1; .14</td><td align="left" rowspan="1" colspan="1">1.37 &#x000b1; .20</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Suboptimal</td><td align="left" rowspan="1" colspan="1">0.93 &#x000b1; .28</td><td align="left" rowspan="1" colspan="1">1.21 &#x000b1; .21</td><td align="left" rowspan="1" colspan="1">1.28 &#x000b1; .20</td><td align="left" rowspan="1" colspan="1">1.14 &#x000b1; .22</td></tr><tr><td align="left" rowspan="1" colspan="1">Collect Latency</td><td align="left" rowspan="1" colspan="1">Optimal</td><td align="left" rowspan="1" colspan="1">1.76 &#x000b1; .11</td><td align="left" rowspan="1" colspan="1">1.80 &#x000b1; .16</td><td align="left" rowspan="1" colspan="1">1.64 &#x000b1; .10</td><td align="left" rowspan="1" colspan="1">1.73 &#x000b1; .13</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Suboptimal</td><td align="left" rowspan="1" colspan="1">1.64 &#x000b1; .21</td><td align="left" rowspan="1" colspan="1">1.37 &#x000b1; .09</td><td align="left" rowspan="1" colspan="1">1.41 &#x000b1; .08</td><td align="left" rowspan="1" colspan="1">1.94 &#x000b1; .65</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec017"><title>Distribution of Responses as Either Optimal or Suboptimal</title><p>To determine the distribution of either optimal or suboptimal responding, the percentage of advantageous choices made was presented as a frequency distribution (<xref ref-type="fig" rid="pone.0155604.g003">Fig 3</xref>). The percentage of advantageous responding was evenly distributed, but had a peak at 61&#x02013;70% of advantageous responses. Eight rats made between 60&#x02013;70% of advantageous responses, and 1&#x02013;3 rats made either 0&#x02013;10, 11&#x02013;20, 21&#x02013;30, 31&#x02013;40, 41&#x02013;50, 51&#x02013;60, 71&#x02013;80 and 91&#x02013;100 percent of advantageous choices. This peak at 61&#x02013;70% accounted for 8 of the 15 rats in the optimal group.</p><fig id="pone.0155604.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0155604.g003</object-id><label>Fig 3</label><caption><p>Top panel: Distribution of percent of Advantageous responding made by rats. Optimal rats were those that made more Advantageous responses during a session. Bottom panel: Mean &#x000b1; SEM percent of advantageous responding on the day before the first drug treatment and the day before the last drug treatment. Data are presented for the Optimal group (open bars, n = 15) and Suboptimal group (dark bars, n = 9). Stability of responding was demonstrated by the lack of any significant effects.</p></caption><graphic xlink:href="pone.0155604.g003"/></fig></sec><sec id="sec018"><title>Stability of Responding Over Test Days</title><p>Analysis of the percent Advantageous choice made either prior to the first or last day of treatment (<xref ref-type="fig" rid="pone.0155604.g003">Fig 3</xref>), revealed no significant Group X Day interaction, but a main effect of Group was found (F(1, 22) = 14.812, p = 0.001), indicating that the Optimal group made more Advantageous choices than the suboptimal group.</p></sec></sec><sec sec-type="conclusions" id="sec019"><title>Discussion</title><p>The present study found that naltrexone improved choice behavior in a subset of rats that made fewer advantageous choices at baseline. It had no effect on rats that made more advantageous choices at baseline. These effects were selective to choice behavior and did not impinge on any other measures of the rGT. Specifically, the choice P1 was most affected by naltrexone in the Suboptimal rats, with an increase in advantageous choices being seen. The responding of rats was stable across days.</p><p>The effect of naltrexone to increase advantageous choices in the suboptimal rats reflects an effect primarily on P1 responses, as significant increases were also seen in P1 responses in the suboptimal group. A lack of effect in the optimal group is not likely due to a ceiling effect, as the overall percentage of P1 responses is lower than it is for the other options, and thus, it is possible that an increase in responding in this group could have been observed if it existed. Instead, an effect on the suboptimal group suggests that some aspect of decision-making was impaired. This conclusion should be somewhat tempered by the fact that no effects were observed in <italic>post hoc</italic> tests of vehicle to different doses when overall responses on the disadvantageous choice was analyzed. Indeed, overall main effects were significant, despite the relatively small sample size (n = 9).</p><p>The rGT is a novel animal model of gambling that is based on the IGT [<xref rid="pone.0155604.ref003" ref-type="bibr">3</xref>]. In this model, animals are required to inhibit &#x02018;tempting&#x02019; options with higher reward (and higher punishment) in favor of response options with fewer rewards that produce more food pellets over time. Some rats make more advantageous choices over sessions, while others prefer the disadvantageous options. Analysis of the percentage of responses of either advantageous or disadvantageous responses made revealed that responding over days remained stable from the start of the dose-response to the end of the dose-response. The distribution of rats into &#x02018;Optimal&#x02019; or &#x02018;Suboptimal&#x02019; groups was evenly distributed over choice options, with the most number of rats making between 60&#x02013;70% of advantageous responses in a given session. Analysis of differences between the Optimal and Suboptimal groups revealed that differences were found only on the Advantageous/Disadvantageous choice and number of trials. The fewer number of trials initiated by the Suboptimal group likely reflects the greater time-out imposed on the choices with higher reward/punishment outcomes. A lack of effect on other measures suggests that these rats did not vary on impulsivity or food motivation. Instead, if these rats represent different subpopulations, differences may be due to different response strategies. Future investigations will need to further explore this.</p><p>Future investigations should further delineate the effect of opiate antagonists on models of gambling behavior, as the present study provides some evidence that naltrexone may be effective in problem gamblers, with no impact on those who adopt healthy gaming. This is an important consideration given that many treatments for substance use disorders have had the problem of side effects that make compliance a challenge [<xref rid="pone.0155604.ref019" ref-type="bibr">19</xref>]. Indeed, no other measures apart from choice were affected in the present study. To the extent that choice in this task represents the same cognitive impairment in the Iowa gambling task [<xref rid="pone.0155604.ref003" ref-type="bibr">3</xref>], this model provides face and construct validity, and the present findings are encouraging in terms of the predictive validity of this task.</p><p>The present findings support a previous study in which no effect of naltrexone was seen on a delayed discounting task [<xref rid="pone.0155604.ref020" ref-type="bibr">20</xref>]. The delay discounting task is a measure of impulsivity and this suggests that naltrexone does not influence impulsivity, consistent with the present finding of no effect on premature responding. Similarly, it is not likely that any effects of naltrexone were due to its ability to affect the palatability of food [<xref rid="pone.0155604.ref021" ref-type="bibr">21</xref>], as responding was increased, while opiate antagonists have primarily been found to decrease, food intake in animal models [<xref rid="pone.0155604.ref022" ref-type="bibr">22</xref>, <xref rid="pone.0155604.ref023" ref-type="bibr">23</xref>]. Similarly, any effects of naltrexone are not likely due to changes in motor activation, as naloxone has been found to decrease [<xref rid="pone.0155604.ref024" ref-type="bibr">24</xref>], or have no effect [<xref rid="pone.0155604.ref025" ref-type="bibr">25</xref>], on motor activation, effects that are opposite in direction to the present findings. Naltrexone has been found to have some effects on memory [<xref rid="pone.0155604.ref026" ref-type="bibr">26</xref>&#x02013;<xref rid="pone.0155604.ref028" ref-type="bibr">28</xref>] and to improve performance on the Morris water maze in rats with vascular dementia [<xref rid="pone.0155604.ref029" ref-type="bibr">29</xref>]. The latter finding is compelling in light of the present findings as it suggests that naltrexone may increase cognitive performance in populations with impairments. Future studies will need to investigate the effects of opiate antagonists on individual differences in performance.</p><p>The present findings are interesting in view of a literature demonstrating that naltrexone decreases measures of seeking and taking of drugs of abuse. For example, naltrexone decreased ethanol drinking in acute [<xref rid="pone.0155604.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0155604.ref030" ref-type="bibr">30</xref>&#x02013;<xref rid="pone.0155604.ref032" ref-type="bibr">32</xref>] and chronic [<xref rid="pone.0155604.ref033" ref-type="bibr">33</xref>] models of ethanol consumption, (but see [<xref rid="pone.0155604.ref034" ref-type="bibr">34</xref>, <xref rid="pone.0155604.ref035" ref-type="bibr">35</xref>]) and also lowered intake of heroin or cocaine/heroin combinations in a self-administration model [<xref rid="pone.0155604.ref036" ref-type="bibr">36</xref>]. Context-induced [<xref rid="pone.0155604.ref037" ref-type="bibr">37</xref>] and ethanol-induced [<xref rid="pone.0155604.ref032" ref-type="bibr">32</xref>] reinstatement of ethanol-seeking as well as amphetamine-induced reinstatement [<xref rid="pone.0155604.ref038" ref-type="bibr">38</xref>] and sensitization [<xref rid="pone.0155604.ref039" ref-type="bibr">39</xref>] were also attenuated. Further findings that naltrexone did not affect food and water intake [<xref rid="pone.0155604.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0155604.ref031" ref-type="bibr">31</xref>, <xref rid="pone.0155604.ref038" ref-type="bibr">38</xref>], or basal locomotion [<xref rid="pone.0155604.ref039" ref-type="bibr">39</xref>] suggest that effects were on some aspect of the addictive properties of the drugs and may provide an account of the present data in terms a cognitive impairment rather than some aspect of satiety or food reward, <italic>per se</italic>.</p><p>In humans, few pharmacological treatment approaches have been used successfully in clinical trials for the treatment of gambling with the exception perhaps of opiate antagonists such as naltrexone [<xref rid="pone.0155604.ref040" ref-type="bibr">40</xref>, <xref rid="pone.0155604.ref041" ref-type="bibr">41</xref>]. That is, patients treated with naltrexone [<xref rid="pone.0155604.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0155604.ref006" ref-type="bibr">6</xref>] or another opiate antagonist, nalmefene [<xref rid="pone.0155604.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0155604.ref013" ref-type="bibr">13</xref>], showed improvement in measures of gambling. Although other medications have shown some efficacy, it was concluded in a meta-analysis that the effects of antidepressants and mood stabilizers may vary based on comorbidity [<xref rid="pone.0155604.ref042" ref-type="bibr">42</xref>]. Indeed, in healthy people, naltrexone was better than topiramate, bupropion or escitlaopram [<xref rid="pone.0155604.ref007" ref-type="bibr">7</xref>]. Acamprosate and baclofen [<xref rid="pone.0155604.ref043" ref-type="bibr">43</xref>] were not effective, while topiramate, bupropion and fluvoxamine had mixed results [<xref rid="pone.0155604.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0155604.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0155604.ref044" ref-type="bibr">44</xref>&#x02013;<xref rid="pone.0155604.ref048" ref-type="bibr">48</xref>]. It should be noted that, in all these studies, participants met the DSM diagnosis for gambling disorder. It is not known whether naltrexone would affect people with healthy gaming, but based on the present results, it can be hypothesized that naltrexone would not have an effect on this population.</p><p>The one other drug that has shown some promise for the treatment of gambling disorder is disulfiram. Traditionally used as a medication for the treatment of alcohol use disorder through inhibition of alcohol dehydrogenase, disulfiram has recently been shown to be effective in cocaine use [<xref rid="pone.0155604.ref049" ref-type="bibr">49</xref>&#x02013;<xref rid="pone.0155604.ref054" ref-type="bibr">54</xref>] suggesting it may have an additional mechanism of action. Based on this, it has been proposed that disulfiram may be an effective treatment for gambling disorder [<xref rid="pone.0155604.ref055" ref-type="bibr">55</xref>]. Indeed, disulfiram has shown promise in reducing gambling in one case report [<xref rid="pone.0155604.ref056" ref-type="bibr">56</xref>]. In another study, no decreases in gambling were observed, but cravings were decreased [<xref rid="pone.0155604.ref057" ref-type="bibr">57</xref>]. Further studies should explore the impact of disulfiram on the rGT.</p></sec><sec sec-type="conclusions" id="sec020"><title>Conclusions</title><p>In conclusion, the present study provides some support for the contention that opiate antagonists may serve as treatments for gambling disorder. It further suggests that the rGT may be used as a pre-clinical method for screening of new drugs. Although compelling as an animal model, the present study is underpowered to do a complete analysis as to the validity of the model and the use of optimal and suboptimal subgroups. In our studies, we have observed that different cohorts of rats have different numbers of optimal and suboptimal rats and that the group differences on measures can vary when the sample sizes are relatively small, as they are in this study for the suboptimal group. Thus, future studies will need to further evaluate the utility of this model for the pre-clinical evaluation of drugs that are in development for the treatment of gambling disorder. Further evaluation of naltrexone as a treatment option for Gambling Disorder is warranted.</p></sec></body><back><ref-list><title>References</title><ref id="pone.0155604.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>de Visser</surname><given-names>L</given-names></name>, <name><surname>Homberg</surname><given-names>JR</given-names></name>, <name><surname>Mitsogiannis</surname><given-names>M</given-names></name>, <name><surname>Zeeb</surname><given-names>FD</given-names></name>, <name><surname>Rivalan</surname><given-names>M</given-names></name>, <name><surname>Fitoussi</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Rodent versions of the iowa gambling task: opportunities and challenges for the understanding of decision-making</article-title>. <source>Frontiers in neuroscience</source>. <year>2011</year>;<volume>5</volume>:<fpage>109</fpage> Epub 2011/10/21. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3389/fnins.2011.00109">10.3389/fnins.2011.00109</ext-link></comment> ; PubMed Central PMCID: PMC3189637.<pub-id pub-id-type="pmid">22013406</pub-id></mixed-citation></ref><ref id="pone.0155604.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Zeeb</surname><given-names>FD</given-names></name>, <name><surname>Robbins</surname><given-names>TW</given-names></name>, <name><surname>Winstanley</surname><given-names>CA</given-names></name>. <article-title>Serotonergic and dopaminergic modulation of gambling behavior as assessed using a novel rat gambling task</article-title>. <source>Neuropsychopharmacology</source>. <year>2009</year>;<volume>34</volume>(<issue>10</issue>):<fpage>2329</fpage>&#x02013;<lpage>43</lpage>. Epub 2009/06/19. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/npp.2009.62">10.1038/npp.2009.62</ext-link></comment> .<pub-id pub-id-type="pmid">19536111</pub-id></mixed-citation></ref><ref id="pone.0155604.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Bechara</surname><given-names>A</given-names></name>, <name><surname>Damasio</surname><given-names>AR</given-names></name>, <name><surname>Damasio</surname><given-names>H</given-names></name>, <name><surname>Anderson</surname><given-names>SW</given-names></name>. <article-title>Insensitivity to future consequences following damage to human prefrontal cortex</article-title>. <source>Cognition</source>. <year>1994</year>;<volume>50</volume>(<issue>1&#x02013;3</issue>):<fpage>7</fpage>&#x02013;<lpage>15</lpage>. Epub 1994/04/01. .<pub-id pub-id-type="pmid">8039375</pub-id></mixed-citation></ref><ref id="pone.0155604.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>SW</given-names></name>, <name><surname>Grant</surname><given-names>JE</given-names></name>, <name><surname>Adson</surname><given-names>DE</given-names></name>, <name><surname>Shin</surname><given-names>YC</given-names></name>. <article-title>Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling</article-title>. <source>Biol Psychiatry</source>. <year>2001</year>;<volume>49</volume>(<issue>11</issue>):<fpage>914</fpage>&#x02013;<lpage>21</lpage>. Epub 2001/05/30. .<pub-id pub-id-type="pmid">11377409</pub-id></mixed-citation></ref><ref id="pone.0155604.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>SW</given-names></name>, <name><surname>Grant</surname><given-names>JE</given-names></name>. <article-title>An open naltrexone treatment study in pathological gambling disorder</article-title>. <source>International clinical psychopharmacology</source>. <year>2001</year>;<volume>16</volume>(<issue>5</issue>):<fpage>285</fpage>&#x02013;<lpage>9</lpage>. Epub 2001/09/13. .<pub-id pub-id-type="pmid">11552772</pub-id></mixed-citation></ref><ref id="pone.0155604.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Grant</surname><given-names>JE</given-names></name>, <name><surname>Kim</surname><given-names>SW</given-names></name>, <name><surname>Hartman</surname><given-names>BK</given-names></name>. <article-title>A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges</article-title>. <source>The Journal of clinical psychiatry</source>. <year>2008</year>;<volume>69</volume>(<issue>5</issue>):<fpage>783</fpage>&#x02013;<lpage>9</lpage>. Epub 2008/04/04. .<pub-id pub-id-type="pmid">18384246</pub-id></mixed-citation></ref><ref id="pone.0155604.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Rosenberg</surname><given-names>O</given-names></name>, <name><surname>Dinur</surname><given-names>LK</given-names></name>, <name><surname>Dannon</surname><given-names>PN</given-names></name>. <article-title>Four-year follow-up study of pharmacological treatment in pathological gamblers</article-title>. <source>Clin Neuropharmacol</source>. <year>2013</year>;<volume>36</volume>(<issue>2</issue>):<fpage>42</fpage>&#x02013;<lpage>5</lpage>. Epub 2013/03/19. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/WNF.0b013e31828740ea">10.1097/WNF.0b013e31828740ea</ext-link></comment> .<pub-id pub-id-type="pmid">23503545</pub-id></mixed-citation></ref><ref id="pone.0155604.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Dannon</surname><given-names>PN</given-names></name>, <name><surname>Lowengrub</surname><given-names>K</given-names></name>, <name><surname>Musin</surname><given-names>E</given-names></name>, <name><surname>Gonopolsky</surname><given-names>Y</given-names></name>, <name><surname>Kotler</surname><given-names>M</given-names></name>. <article-title>12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study</article-title>. <source>J Clin Psychopharmacol</source>. <year>2007</year>;<volume>27</volume>(<issue>6</issue>):<fpage>620</fpage>&#x02013;<lpage>4</lpage>. Epub 2007/11/16. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/jcp.0b013e31815a4400">10.1097/jcp.0b013e31815a4400</ext-link></comment> .<pub-id pub-id-type="pmid">18004130</pub-id></mixed-citation></ref><ref id="pone.0155604.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Dannon</surname><given-names>PN</given-names></name>, <name><surname>Lowengrub</surname><given-names>K</given-names></name>, <name><surname>Musin</surname><given-names>E</given-names></name>, <name><surname>Gonopolski</surname><given-names>Y</given-names></name>, <name><surname>Kotler</surname><given-names>M</given-names></name>. <article-title>Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study</article-title>. <source>J Clin Psychopharmacol</source>. <year>2005</year>;<volume>25</volume>(<issue>6</issue>):<fpage>593</fpage>&#x02013;<lpage>6</lpage>. Epub 2005/11/12. .<pub-id pub-id-type="pmid">16282845</pub-id></mixed-citation></ref><ref id="pone.0155604.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>SW</given-names></name>. <article-title>Opioid antagonists in the treatment of impulse-control disorders</article-title>. <source>The Journal of clinical psychiatry</source>. <year>1998</year>;<volume>59</volume>(<issue>4</issue>):<fpage>159</fpage>&#x02013;<lpage>64</lpage>. Epub 1998/05/20. .<pub-id pub-id-type="pmid">9590665</pub-id></mixed-citation></ref><ref id="pone.0155604.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Yoon</surname><given-names>G</given-names></name>, <name><surname>Kim</surname><given-names>SW</given-names></name>. <article-title>Monthly injectable naltrexone for pathological gambling</article-title>. <source>Am J Psychiatry</source>. <year>2013</year>;<volume>170</volume>(<issue>6</issue>):<fpage>682</fpage>&#x02013;<lpage>3</lpage>. Epub 2013/06/05. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1176/appi.ajp.2013.12111469">10.1176/appi.ajp.2013.12111469</ext-link></comment> .<pub-id pub-id-type="pmid">23732971</pub-id></mixed-citation></ref><ref id="pone.0155604.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Grant</surname><given-names>JE</given-names></name>, <name><surname>Odlaug</surname><given-names>BL</given-names></name>, <name><surname>Potenza</surname><given-names>MN</given-names></name>, <name><surname>Hollander</surname><given-names>E</given-names></name>, <name><surname>Kim</surname><given-names>SW</given-names></name>. <article-title>Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study</article-title>. <source>Br J Psychiatry</source>. <year>2010</year>;<volume>197</volume>(<issue>4</issue>):<fpage>330</fpage>&#x02013;<lpage>1</lpage>. Epub 2010/10/05. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1192/bjp.bp.110.078105">10.1192/bjp.bp.110.078105</ext-link></comment> .<pub-id pub-id-type="pmid">20884959</pub-id></mixed-citation></ref><ref id="pone.0155604.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Grant</surname><given-names>JE</given-names></name>, <name><surname>Potenza</surname><given-names>MN</given-names></name>, <name><surname>Hollander</surname><given-names>E</given-names></name>, <name><surname>Cunningham-Williams</surname><given-names>R</given-names></name>, <name><surname>Nurminen</surname><given-names>T</given-names></name>, <name><surname>Smits</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling</article-title>. <source>Am J Psychiatry</source>. <year>2006</year>;<volume>163</volume>(<issue>2</issue>):<fpage>303</fpage>&#x02013;<lpage>12</lpage>. Epub 2006/02/02. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1176/appi.ajp.163.2.303">10.1176/appi.ajp.163.2.303</ext-link></comment> .<pub-id pub-id-type="pmid">16449486</pub-id></mixed-citation></ref><ref id="pone.0155604.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Linnet</surname><given-names>J</given-names></name>, <name><surname>Rojskjaer</surname><given-names>S</given-names></name>, <name><surname>Nygaard</surname><given-names>J</given-names></name>, <name><surname>Maher</surname><given-names>BA</given-names></name>. <article-title>Episodic chasing in pathological gamblers using the Iowa gambling task</article-title>. <source>Scandinavian journal of psychology</source>. <year>2006</year>;<volume>47</volume>(<issue>1</issue>):<fpage>43</fpage>&#x02013;<lpage>9</lpage>. Epub 2006/01/26. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1467-9450.2006.00491.x">10.1111/j.1467-9450.2006.00491.x</ext-link></comment> .<pub-id pub-id-type="pmid">16433661</pub-id></mixed-citation></ref><ref id="pone.0155604.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Baarendse</surname><given-names>PJ</given-names></name>, <name><surname>Winstanley</surname><given-names>CA</given-names></name>, <name><surname>Vanderschuren</surname><given-names>LJ</given-names></name>. <article-title>Simultaneous blockade of dopamine and noradrenaline reuptake promotes disadvantageous decision making in a rat gambling task</article-title>. <source>Psychopharmacology (Berl)</source>. <year>2013</year>;<volume>225</volume>(<issue>3</issue>):<fpage>719</fpage>&#x02013;<lpage>31</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00213-012-2857-z">10.1007/s00213-012-2857-z</ext-link></comment> ; PubMed Central PMCID: PMC3531574.<pub-id pub-id-type="pmid">22968659</pub-id></mixed-citation></ref><ref id="pone.0155604.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Stromberg</surname><given-names>MF</given-names></name>, <name><surname>Sengpiel</surname><given-names>T</given-names></name>, <name><surname>Mackler</surname><given-names>SA</given-names></name>, <name><surname>Volpicelli</surname><given-names>JR</given-names></name>, <name><surname>O'Brien</surname><given-names>CP</given-names></name>, <name><surname>Vogel</surname><given-names>WH</given-names></name>. <article-title>Effect of naltrexone on oral consumption of concurrently available ethanol and cocaine in the rat</article-title>. <source>Alcohol</source>. <year>2002</year>;<volume>28</volume>(<issue>3</issue>):<fpage>169</fpage>&#x02013;<lpage>79</lpage>. Epub 2003/01/29. .<pub-id pub-id-type="pmid">12551758</pub-id></mixed-citation></ref><ref id="pone.0155604.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Robbins</surname><given-names>TW</given-names></name>. <article-title>The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry</article-title>. <source>Psychopharmacology (Berl)</source>. <year>2002</year>;<volume>163</volume>(<issue>3&#x02013;4</issue>):<fpage>362</fpage>&#x02013;<lpage>80</lpage>. Epub 2002/10/10. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00213-002-1154-7">10.1007/s00213-002-1154-7</ext-link></comment> .<pub-id pub-id-type="pmid">12373437</pub-id></mixed-citation></ref><ref id="pone.0155604.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Petry</surname><given-names>NM</given-names></name>. <article-title>Substance abuse, pathological gambling, and impulsiveness</article-title>. <source>Drug Alcohol Depend</source>. <year>2001</year>;<volume>63</volume>(<issue>1</issue>):<fpage>29</fpage>&#x02013;<lpage>38</lpage>. Epub 2001/04/12. .<pub-id pub-id-type="pmid">11297829</pub-id></mixed-citation></ref><ref id="pone.0155604.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Le Foll</surname><given-names>B</given-names></name>, <name><surname>Wilson</surname><given-names>AA</given-names></name>, <name><surname>Graff</surname><given-names>A</given-names></name>, <name><surname>Boileau</surname><given-names>I</given-names></name>, <name><surname>Di Ciano</surname><given-names>P</given-names></name>. <article-title>Recent methods for measuring dopamine D3 receptor occupancy in vivo: importance for drug development</article-title>. <source>Frontiers in pharmacology</source>. <year>2014</year>;<volume>5</volume>:<fpage>161</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3389/fphar.2014.00161">10.3389/fphar.2014.00161</ext-link></comment> ; PubMed Central PMCID: PMC4090596.<pub-id pub-id-type="pmid">25071579</pub-id></mixed-citation></ref><ref id="pone.0155604.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Kieres</surname><given-names>AK</given-names></name>, <name><surname>Hausknecht</surname><given-names>KA</given-names></name>, <name><surname>Farrar</surname><given-names>AM</given-names></name>, <name><surname>Acheson</surname><given-names>A</given-names></name>, <name><surname>de Wit</surname><given-names>H</given-names></name>, <name><surname>Richards</surname><given-names>JB</given-names></name>. <article-title>Effects of morphine and naltrexone on impulsive decision making in rats</article-title>. <source>Psychopharmacology (Berl)</source>. <year>2004</year>;<volume>173</volume>(<issue>1&#x02013;2</issue>):<fpage>167</fpage>&#x02013;<lpage>74</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00213-003-1697-2">10.1007/s00213-003-1697-2</ext-link></comment> .<pub-id pub-id-type="pmid">14752586</pub-id></mixed-citation></ref><ref id="pone.0155604.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Goodwin</surname><given-names>FL</given-names></name>, <name><surname>Campisi</surname><given-names>M</given-names></name>, <name><surname>Babinska</surname><given-names>I</given-names></name>, <name><surname>Amit</surname><given-names>Z</given-names></name>. <article-title>Effects of naltrexone on the intake of ethanol and flavored solutions in rats</article-title>. <source>Alcohol</source>. <year>2001</year>;<volume>25</volume>(<issue>1</issue>):<fpage>9</fpage>&#x02013;<lpage>19</lpage>. .<pub-id pub-id-type="pmid">11668013</pub-id></mixed-citation></ref><ref id="pone.0155604.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Corwin</surname><given-names>RL</given-names></name>, <name><surname>Wojnicki</surname><given-names>FH</given-names></name>. <article-title>Baclofen, raclopride, and naltrexone differentially affect intake of fat and sucrose under limited access conditions</article-title>. <source>Behav Pharmacol</source>. <year>2009</year>;<volume>20</volume>(<issue>5&#x02013;6</issue>):<fpage>537</fpage>&#x02013;<lpage>48</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/FBP.0b013e3283313168">10.1097/FBP.0b013e3283313168</ext-link></comment> .<pub-id pub-id-type="pmid">19724193</pub-id></mixed-citation></ref><ref id="pone.0155604.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Cooper</surname><given-names>SJ</given-names></name>. <article-title>Naloxone: effects on food and water consumption in the non-deprived and deprived rat</article-title>. <source>Psychopharmacology (Berl)</source>. <year>1980</year>;<volume>71</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>6</lpage>. .<pub-id pub-id-type="pmid">6779317</pub-id></mixed-citation></ref><ref id="pone.0155604.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>DeRossett</surname><given-names>SE</given-names></name>, <name><surname>Holtzman</surname><given-names>SG</given-names></name>. <article-title>Effects of naloxone and diprenorphine on spontaneous activity in rats and mice</article-title>. <source>Pharmacol Biochem Behav</source>. <year>1982</year>;<volume>17</volume>(<issue>2</issue>):<fpage>347</fpage>&#x02013;<lpage>51</lpage>. .<pub-id pub-id-type="pmid">7134243</pub-id></mixed-citation></ref><ref id="pone.0155604.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Amir</surname><given-names>S</given-names></name>, <name><surname>Solomon</surname><given-names>M</given-names></name>, <name><surname>Amit</surname><given-names>Z</given-names></name>. <article-title>The effect of acute and chronic naloxone administration on motor activation in the rat</article-title>. <source>Neuropharmacology</source>. <year>1979</year>;<volume>18</volume>(<issue>2</issue>):<fpage>171</fpage>&#x02013;<lpage>3</lpage>. .<pub-id pub-id-type="pmid">431784</pub-id></mixed-citation></ref><ref id="pone.0155604.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Fanselow</surname><given-names>MS</given-names></name>, <name><surname>Calcagnetti</surname><given-names>DJ</given-names></name>, <name><surname>Helmstetter</surname><given-names>FJ</given-names></name>. <article-title>Peripheral versus intracerebroventricular administration of quaternary naltrexone and the enhancement of Pavlovian conditioning</article-title>. <source>Brain Res</source>. <year>1988</year>;<volume>444</volume>(<issue>1</issue>):<fpage>147</fpage>&#x02013;<lpage>52</lpage>. .<pub-id pub-id-type="pmid">3359284</pub-id></mixed-citation></ref><ref id="pone.0155604.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Izquierdo</surname><given-names>I</given-names></name>. <article-title>Effect of naloxone and morphine on various forms of memory in the rat: possible role of engogenous opiate mechanisms in memory consolidation</article-title>. <source>Psychopharmacology (Berl)</source>. <year>1979</year>;<volume>66</volume>(<issue>2</issue>):<fpage>199</fpage>&#x02013;<lpage>203</lpage>. .<pub-id pub-id-type="pmid">119264</pub-id></mixed-citation></ref><ref id="pone.0155604.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Izquierdo</surname><given-names>I</given-names></name>. <article-title>Effect of beta-endorphin and naloxone on acquisition, memory, and retrieval of shuttle avoidance and habituation learning in rats</article-title>. <source>Psychopharmacology (Berl)</source>. <year>1980</year>;<volume>69</volume>(<issue>1</issue>):<fpage>111</fpage>&#x02013;<lpage>5</lpage>. .<pub-id pub-id-type="pmid">6248917</pub-id></mixed-citation></ref><ref id="pone.0155604.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Shi-Lei</surname><given-names>S</given-names></name>, <name><surname>Xiao-Hu</surname><given-names>X</given-names></name>, <name><surname>Guang-Yu</surname><given-names>M</given-names></name>, <name><surname>Xu</surname><given-names>H</given-names></name>. <article-title>Effect of naloxone on cognitive function in vascular dementia in rats</article-title>. <source>The Indian journal of medical research</source>. <year>2002</year>;<volume>115</volume>:<fpage>265</fpage>&#x02013;<lpage>71</lpage>. .<pub-id pub-id-type="pmid">12440200</pub-id></mixed-citation></ref><ref id="pone.0155604.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Stromberg</surname><given-names>MF</given-names></name>, <name><surname>Casale</surname><given-names>M</given-names></name>, <name><surname>Volpicelli</surname><given-names>L</given-names></name>, <name><surname>Volpicelli</surname><given-names>JR</given-names></name>, <name><surname>O'Brien</surname><given-names>CP</given-names></name>. <article-title>A comparison of the effects of the opioid antagonists naltrexone, naltrindole, and beta-funaltrexamine on ethanol consumption in the rat</article-title>. <source>Alcohol</source>. <year>1998</year>;<volume>15</volume>(<issue>4</issue>):<fpage>281</fpage>&#x02013;<lpage>9</lpage>. .<pub-id pub-id-type="pmid">9590512</pub-id></mixed-citation></ref><ref id="pone.0155604.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Myers</surname><given-names>RD</given-names></name>, <name><surname>Lankford</surname><given-names>MF</given-names></name>. <article-title>Suppression of alcohol preference in high alcohol drinking rats: efficacy of amperozide versus naltrexone</article-title>. <source>Neuropsychopharmacology</source>. <year>1996</year>;<volume>14</volume>(<issue>2</issue>):<fpage>139</fpage>&#x02013;<lpage>49</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/0893-133X(95)00081-N">10.1016/0893-133X(95)00081-N</ext-link></comment> .<pub-id pub-id-type="pmid">8822536</pub-id></mixed-citation></ref><ref id="pone.0155604.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Bienkowski</surname><given-names>P</given-names></name>, <name><surname>Kostowski</surname><given-names>W</given-names></name>, <name><surname>Koros</surname><given-names>E</given-names></name>. <article-title>Ethanol-reinforced behaviour in the rat: effects of naltrexone</article-title>. <source>Eur J Pharmacol</source>. <year>1999</year>;<volume>374</volume>(<issue>3</issue>):<fpage>321</fpage>&#x02013;<lpage>7</lpage>. .<pub-id pub-id-type="pmid">10422776</pub-id></mixed-citation></ref><ref id="pone.0155604.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Stromberg</surname><given-names>MF</given-names></name>, <name><surname>Volpicelli</surname><given-names>JR</given-names></name>, <name><surname>O'Brien</surname><given-names>CP</given-names></name>. <article-title>Effects of naltrexone administered repeatedly across 30 or 60 days on ethanol consumption using a limited access procedure in the rat</article-title>. <source>Alcohol Clin Exp Res</source>. <year>1998</year>;<volume>22</volume>(<issue>9</issue>):<fpage>2186</fpage>&#x02013;<lpage>91</lpage>. .<pub-id pub-id-type="pmid">9884167</pub-id></mixed-citation></ref><ref id="pone.0155604.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Juarez</surname><given-names>J</given-names></name>, <name><surname>Barrios De Tomasi</surname><given-names>E</given-names></name>. <article-title>Naltrexone treatment produces dose-related effects on food and water intake but daily alcohol consumption is not affected</article-title>. <source>Nutritional neuroscience</source>. <year>2008</year>;<volume>11</volume>(<issue>4</issue>):<fpage>183</fpage>&#x02013;<lpage>92</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1179/147683008X301577">10.1179/147683008X301577</ext-link></comment> .<pub-id pub-id-type="pmid">18681987</pub-id></mixed-citation></ref><ref id="pone.0155604.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Juarez</surname><given-names>J</given-names></name>, <name><surname>Eliana Bde</surname><given-names>T</given-names></name>. <article-title>Alcohol consumption is enhanced after naltrexone treatment</article-title>. <source>Alcohol Clin Exp Res</source>. <year>2007</year>;<volume>31</volume>(<issue>2</issue>):<fpage>260</fpage>&#x02013;<lpage>4</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1530-0277.2006.00313.x">10.1111/j.1530-0277.2006.00313.x</ext-link></comment> .<pub-id pub-id-type="pmid">17250617</pub-id></mixed-citation></ref><ref id="pone.0155604.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Hemby</surname><given-names>SE</given-names></name>, <name><surname>Smith</surname><given-names>JE</given-names></name>, <name><surname>Dworkin</surname><given-names>SI</given-names></name>. <article-title>The effects of eticlopride and naltrexone on responding maintained by food, cocaine, heroin and cocaine/heroin combinations in rats</article-title>. <source>J Pharmacol Exp Ther</source>. <year>1996</year>;<volume>277</volume>(<issue>3</issue>):<fpage>1247</fpage>&#x02013;<lpage>58</lpage>. .<pub-id pub-id-type="pmid">8667185</pub-id></mixed-citation></ref><ref id="pone.0155604.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Burattini</surname><given-names>C</given-names></name>, <name><surname>Gill</surname><given-names>TM</given-names></name>, <name><surname>Aicardi</surname><given-names>G</given-names></name>, <name><surname>Janak</surname><given-names>PH</given-names></name>. <article-title>The ethanol self-administration context as a reinstatement cue: acute effects of naltrexone</article-title>. <source>Neuroscience</source>. <year>2006</year>;<volume>139</volume>(<issue>3</issue>):<fpage>877</fpage>&#x02013;<lpage>87</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.neuroscience.2006.01.009">10.1016/j.neuroscience.2006.01.009</ext-link></comment> .<pub-id pub-id-type="pmid">16516392</pub-id></mixed-citation></ref><ref id="pone.0155604.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Haggkvist</surname><given-names>J</given-names></name>, <name><surname>Lindholm</surname><given-names>S</given-names></name>, <name><surname>Franck</surname><given-names>J</given-names></name>. <article-title>The opioid receptor antagonist naltrexone attenuates reinstatement of amphetamine drug-seeking in the rat</article-title>. <source>Behav Brain Res</source>. <year>2009</year>;<volume>197</volume>(<issue>1</issue>):<fpage>219</fpage>&#x02013;<lpage>24</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.bbr.2008.08.021">10.1016/j.bbr.2008.08.021</ext-link></comment> .<pub-id pub-id-type="pmid">18793682</pub-id></mixed-citation></ref><ref id="pone.0155604.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Haggkvist</surname><given-names>J</given-names></name>, <name><surname>Bjorkholm</surname><given-names>C</given-names></name>, <name><surname>Steensland</surname><given-names>P</given-names></name>, <name><surname>Lindholm</surname><given-names>S</given-names></name>, <name><surname>Franck</surname><given-names>J</given-names></name>, <name><surname>Schilstrom</surname><given-names>B</given-names></name>. <article-title>Naltrexone attenuates amphetamine-induced locomotor sensitization in the rat</article-title>. <source>Addict Biol</source>. <year>2011</year>;<volume>16</volume>(<issue>1</issue>):<fpage>20</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1369-1600.2009.00199.x">10.1111/j.1369-1600.2009.00199.x</ext-link></comment> .<pub-id pub-id-type="pmid">20192948</pub-id></mixed-citation></ref><ref id="pone.0155604.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Grant</surname><given-names>JE</given-names></name>, <name><surname>Kim</surname><given-names>SW</given-names></name>, <name><surname>Potenza</surname><given-names>MN</given-names></name>. <article-title>Advances in the pharmacological treatment of pathological gambling</article-title>. <source>J Gambl Stud</source>. <year>2003</year>;<volume>19</volume>(<issue>1</issue>):<fpage>85</fpage>&#x02013;<lpage>109</lpage>. Epub 2003/03/15. .<pub-id pub-id-type="pmid">12635541</pub-id></mixed-citation></ref><ref id="pone.0155604.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Grant</surname><given-names>JE</given-names></name>, <name><surname>Odlaug</surname><given-names>BL</given-names></name>, <name><surname>Schreiber</surname><given-names>LR</given-names></name>. <article-title>Pharmacological treatments in pathological gambling</article-title>. <source>British journal of clinical pharmacology</source>. <year>2014</year>;<volume>77</volume>(<issue>2</issue>):<fpage>375</fpage>&#x02013;<lpage>81</lpage>. Epub 2012/09/18. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1365-2125.2012.04457.x">10.1111/j.1365-2125.2012.04457.x</ext-link></comment> .<pub-id pub-id-type="pmid">22979951</pub-id></mixed-citation></ref><ref id="pone.0155604.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Pallesen</surname><given-names>S</given-names></name>, <name><surname>Molde</surname><given-names>H</given-names></name>, <name><surname>Arnestad</surname><given-names>HM</given-names></name>, <name><surname>Laberg</surname><given-names>JC</given-names></name>, <name><surname>Skutle</surname><given-names>A</given-names></name>, <name><surname>Iversen</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>Outcome of pharmacological treatments of pathological gambling: a review and meta-analysis</article-title>. <source>J Clin Psychopharmacol</source>. <year>2007</year>;<volume>27</volume>(<issue>4</issue>):<fpage>357</fpage>&#x02013;<lpage>64</lpage>. Epub 2007/07/17. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/jcp.013e3180dcc304d">10.1097/jcp.013e3180dcc304d</ext-link></comment> .<pub-id pub-id-type="pmid">17632219</pub-id></mixed-citation></ref><ref id="pone.0155604.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Dannon</surname><given-names>PN</given-names></name>, <name><surname>Rosenberg</surname><given-names>O</given-names></name>, <name><surname>Schoenfeld</surname><given-names>N</given-names></name>, <name><surname>Kotler</surname><given-names>M</given-names></name>. <article-title>Acamprosate and Baclofen were Not Effective in the Treatment of Pathological Gambling: Preliminary Blind Rater Comparison Study</article-title>. <source>Frontiers in psychiatry</source>. <year>2011</year>;<volume>2</volume>:<fpage>33</fpage> Epub 2011/06/30. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3389/fpsyt.2011.00033">10.3389/fpsyt.2011.00033</ext-link></comment> ; PubMed Central PMCID: PMC3112314.<pub-id pub-id-type="pmid">21713109</pub-id></mixed-citation></ref><ref id="pone.0155604.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Dannon</surname><given-names>PN</given-names></name>, <name><surname>Lowengrub</surname><given-names>K</given-names></name>, <name><surname>Gonopolski</surname><given-names>Y</given-names></name>, <name><surname>Musin</surname><given-names>E</given-names></name>, <name><surname>Kotler</surname><given-names>M</given-names></name>. <article-title>Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study</article-title>. <source>Clin Neuropharmacol</source>. <year>2005</year>;<volume>28</volume>(<issue>1</issue>):<fpage>6</fpage>&#x02013;<lpage>10</lpage>. Epub 2005/02/16. .<pub-id pub-id-type="pmid">15711432</pub-id></mixed-citation></ref><ref id="pone.0155604.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Berlin</surname><given-names>HA</given-names></name>, <name><surname>Braun</surname><given-names>A</given-names></name>, <name><surname>Simeon</surname><given-names>D</given-names></name>, <name><surname>Koran</surname><given-names>LM</given-names></name>, <name><surname>Potenza</surname><given-names>MN</given-names></name>, <name><surname>McElroy</surname><given-names>SL</given-names></name>, <etal>et al</etal>
<article-title>A double-blind, placebo-controlled trial of topiramate for pathological gambling</article-title>. <source>The world journal of biological psychiatry: the official journal of the World Federation of Societies of Biological Psychiatry</source>. <year>2013</year>;<volume>14</volume>(<issue>2</issue>):<fpage>121</fpage>&#x02013;<lpage>8</lpage>. Epub 2011/04/14. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3109/15622975.2011.560964">10.3109/15622975.2011.560964</ext-link></comment> .<pub-id pub-id-type="pmid">21486110</pub-id></mixed-citation></ref><ref id="pone.0155604.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Black</surname><given-names>DW</given-names></name>, <name><surname>Arndt</surname><given-names>S</given-names></name>, <name><surname>Coryell</surname><given-names>WH</given-names></name>, <name><surname>Argo</surname><given-names>T</given-names></name>, <name><surname>Forbush</surname><given-names>KT</given-names></name>, <name><surname>Shaw</surname><given-names>MC</given-names></name>, <etal>et al</etal>
<article-title>Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study</article-title>. <source>J Clin Psychopharmacol</source>. <year>2007</year>;<volume>27</volume>(<issue>2</issue>):<fpage>143</fpage>&#x02013;<lpage>50</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/01.jcp.0000264985.25109.25">10.1097/01.jcp.0000264985.25109.25</ext-link></comment> .<pub-id pub-id-type="pmid">17414236</pub-id></mixed-citation></ref><ref id="pone.0155604.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Blanco</surname><given-names>C</given-names></name>, <name><surname>Petkova</surname><given-names>E</given-names></name>, <name><surname>Ibanez</surname><given-names>A</given-names></name>, <name><surname>Saiz-Ruiz</surname><given-names>J</given-names></name>. <article-title>A pilot placebo-controlled study of fluvoxamine for pathological gambling</article-title>. <source>Annals of clinical psychiatry: official journal of the American Academy of Clinical Psychiatrists</source>. <year>2002</year>;<volume>14</volume>(<issue>1</issue>):<fpage>9</fpage>&#x02013;<lpage>15</lpage>. .<pub-id pub-id-type="pmid">12046642</pub-id></mixed-citation></ref><ref id="pone.0155604.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Hollander</surname><given-names>E</given-names></name>, <name><surname>DeCaria</surname><given-names>CM</given-names></name>, <name><surname>Finkell</surname><given-names>JN</given-names></name>, <name><surname>Begaz</surname><given-names>T</given-names></name>, <name><surname>Wong</surname><given-names>CM</given-names></name>, <name><surname>Cartwright</surname><given-names>C</given-names></name>. <article-title>A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling</article-title>. <source>Biol Psychiatry</source>. <year>2000</year>;<volume>47</volume>(<issue>9</issue>):<fpage>813</fpage>&#x02013;<lpage>7</lpage>. .<pub-id pub-id-type="pmid">10812040</pub-id></mixed-citation></ref><ref id="pone.0155604.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Carroll</surname><given-names>KM</given-names></name>, <name><surname>Fenton</surname><given-names>LR</given-names></name>, <name><surname>Ball</surname><given-names>SA</given-names></name>, <name><surname>Nich</surname><given-names>C</given-names></name>, <name><surname>Frankforter</surname><given-names>TL</given-names></name>, <name><surname>Shi</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial</article-title>. <source>Arch Gen Psychiatry</source>. <year>2004</year>;<volume>61</volume>(<issue>3</issue>):<fpage>264</fpage>&#x02013;<lpage>72</lpage>. Epub 2004/03/03. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/archpsyc.61.3.264">10.1001/archpsyc.61.3.264</ext-link></comment> 61/3/264 [pii]. .<pub-id pub-id-type="pmid">14993114</pub-id></mixed-citation></ref><ref id="pone.0155604.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>George</surname><given-names>TP</given-names></name>, <name><surname>Chawarski</surname><given-names>MC</given-names></name>, <name><surname>Pakes</surname><given-names>J</given-names></name>, <name><surname>Carroll</surname><given-names>KM</given-names></name>, <name><surname>Kosten</surname><given-names>TR</given-names></name>, <name><surname>Schottenfeld</surname><given-names>RS</given-names></name>. <article-title>Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial</article-title>. <source>Biol Psychiatry</source>. <year>2000</year>;<volume>47</volume>(<issue>12</issue>):<fpage>1080</fpage>&#x02013;<lpage>6</lpage>. Epub 2000/06/23. doi: S0006322399003108 [pii]. .<pub-id pub-id-type="pmid">10862808</pub-id></mixed-citation></ref><ref id="pone.0155604.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Petrakis</surname><given-names>IL</given-names></name>, <name><surname>Carroll</surname><given-names>KM</given-names></name>, <name><surname>Nich</surname><given-names>C</given-names></name>, <name><surname>Gordon</surname><given-names>LT</given-names></name>, <name><surname>McCance-Katz</surname><given-names>EF</given-names></name>, <name><surname>Frankforter</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts</article-title>. <source>Addiction</source>. <year>2000</year>;<volume>95</volume>(<issue>2</issue>):<fpage>219</fpage>&#x02013;<lpage>28</lpage>. Epub 2000/03/21. .<pub-id pub-id-type="pmid">10723850</pub-id></mixed-citation></ref><ref id="pone.0155604.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Sofuoglu</surname><given-names>M</given-names></name>, <name><surname>Kosten</surname><given-names>TR</given-names></name>. <article-title>Emerging pharmacological strategies in the fight against cocaine addiction</article-title>. <source>Expert opinion on emerging drugs</source>. <year>2006</year>;<volume>11</volume>(<issue>1</issue>):<fpage>91</fpage>&#x02013;<lpage>8</lpage>. Epub 2006/03/01. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1517/14728214.11.1.91">10.1517/14728214.11.1.91</ext-link></comment> .<pub-id pub-id-type="pmid">16503828</pub-id></mixed-citation></ref><ref id="pone.0155604.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Kosten</surname><given-names>TR</given-names></name>, <name><surname>Wu</surname><given-names>G</given-names></name>, <name><surname>Huang</surname><given-names>W</given-names></name>, <name><surname>Harding</surname><given-names>MJ</given-names></name>, <name><surname>Hamon</surname><given-names>SC</given-names></name>, <name><surname>Lappalainen</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine beta-hydroxylase</article-title>. <source>Biol Psychiatry</source>. <year>2013</year>;<volume>73</volume>(<issue>3</issue>):<fpage>219</fpage>&#x02013;<lpage>24</lpage>. Epub 2012/08/22. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.biopsych.2012.07.011">10.1016/j.biopsych.2012.07.011</ext-link></comment> ; PubMed Central PMCID: PMC3514624.<pub-id pub-id-type="pmid">22906516</pub-id></mixed-citation></ref><ref id="pone.0155604.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Schroeder</surname><given-names>JP</given-names></name>, <name><surname>Cooper</surname><given-names>DA</given-names></name>, <name><surname>Schank</surname><given-names>JR</given-names></name>, <name><surname>Lyle</surname><given-names>MA</given-names></name>, <name><surname>Gaval-Cruz</surname><given-names>M</given-names></name>, <name><surname>Ogbonmwan</surname><given-names>YE</given-names></name>, <etal>et al</etal>
<article-title>Disulfiram attenuates drug-primed reinstatement of cocaine seeking via inhibition of dopamine beta-hydroxylase</article-title>. <source>Neuropsychopharmacology</source>. <year>2010</year>;<volume>35</volume>(<issue>12</issue>):<fpage>2440</fpage>&#x02013;<lpage>9</lpage>. Epub 2010/08/26. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/npp.2010.127">10.1038/npp.2010.127</ext-link></comment> ; PubMed Central PMCID: PMC2956132.<pub-id pub-id-type="pmid">20736996</pub-id></mixed-citation></ref><ref id="pone.0155604.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Mutschler</surname><given-names>J</given-names></name>, <name><surname>Buhler</surname><given-names>M</given-names></name>, <name><surname>Diehl</surname><given-names>A</given-names></name>, <name><surname>Mann</surname><given-names>K</given-names></name>, <name><surname>Kiefer</surname><given-names>F</given-names></name>. <article-title>Disulfiram, an old drug with new potential in the treatment of pathological gambling?</article-title>
<source>Medical hypotheses</source>. <year>2010</year>;<volume>74</volume>(<issue>1</issue>):<fpage>209</fpage>&#x02013;<lpage>10</lpage>. Epub 2009/08/08. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.mehy.2009.07.007">10.1016/j.mehy.2009.07.007</ext-link></comment> .<pub-id pub-id-type="pmid">19660874</pub-id></mixed-citation></ref><ref id="pone.0155604.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Mutschler</surname><given-names>J</given-names></name>, <name><surname>Buhler</surname><given-names>M</given-names></name>, <name><surname>Grosshans</surname><given-names>M</given-names></name>, <name><surname>Diehl</surname><given-names>A</given-names></name>, <name><surname>Mann</surname><given-names>K</given-names></name>, <name><surname>Kiefer</surname><given-names>F</given-names></name>. <article-title>Disulfiram, an option for the treatment of pathological gambling?</article-title>
<source>Alcohol Alcohol</source>. <year>2010</year>;<volume>45</volume>(<issue>2</issue>):<fpage>214</fpage>&#x02013;<lpage>6</lpage>. Epub 2010/01/20. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/alcalc/agp093">10.1093/alcalc/agp093</ext-link></comment> .<pub-id pub-id-type="pmid">20083479</pub-id></mixed-citation></ref><ref id="pone.0155604.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Muller</surname><given-names>CA</given-names></name>, <name><surname>Banas</surname><given-names>R</given-names></name>, <name><surname>Heinz</surname><given-names>A</given-names></name>, <name><surname>Hein</surname><given-names>J</given-names></name>. <article-title>Treatment of pathological gambling with disulfiram: a report of 2 cases</article-title>. <source>Pharmacopsychiatry</source>. <year>2011</year>;<volume>44</volume>(<issue>2</issue>):<fpage>81</fpage>&#x02013;<lpage>3</lpage>. Epub 2011/02/18. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1055/s-0031-1271683">10.1055/s-0031-1271683</ext-link></comment> .<pub-id pub-id-type="pmid">21328196</pub-id></mixed-citation></ref></ref-list></back></article>